Protein
Protein (NP_001762)
SIGLEC-2
B-cell receptor CD22 (B-lymphocyte cell adhesion molecule) (BL-CAM) (Sialic acid-binding Ig-like lectin 2) (Siglec-2) (T-cell surface antigen Leu-14) (CD antigen CD22)
CD22
CD22 molecule
Curated
I-type lectin
I-Type Lectins - Siglecs common to mammals
b-sandwich / Ig-like
MHLLGPWLLLLVLEYLAFSDSSKWVFEHPETLYAWEGACVWIPCTYRALDGDLESFILFHNPEYNKNTSKFDGTRLYESTKDGKVPSEQKRVQFLGDKNKNCTLSIHPVHLNDSGQLGLRMESKTEKWMERIHLNVSERPFPPHIQLPPEIQESQEVTLTCLLNFSCYGYPIQLQWLLEGVPMRQAAVTSTSLTIKSVFTRSELKFSPQWSHHGKIVTCQLQDADGKFLSNDTVQLNVKHTPKLEIKVTPSDAIVREGDSVTMTCEVSSSNPEYTTVSWLKDGTSLKKQNTFTLNLREVTKDQSGKYCCQVSNDVGPGRSEEVFLQVQYAPEPSTVQILHSPAVEGSQVEFLCMSLANPLPTNYTWYHNGKEMQGRTEEKVHIPKILPWHAGTYSCVAENILGTGQRGPGAELDVQYPPKKVTTVIQNPMPIREGDTVTLSCNYNSSNPSVTRYEWKPHGAWEEPSLGVLKIQNVGWDNTTIACAACNSWCSWASPVALNVQYAPRDVRVRKIKPLSEIHSGNSVSLQCDFSSSHPKEVQFFWEKNGRLLGKESQLNFDSISPEDAGSYSCWVNNSIGQTASKAWTLEVLYAPRRLRVSMSPGDQVMEGKSATLTCESDANPPVSHYTWFDWNNQSLPYHSQKLRLEPVKVQHSGAYWCQGTNSVGKGRSPLSTLTVYYSPETIGRRVAVGLGSCLAILILAICGLKLQRRWKRTQSQQGLQENSSGQSFFVRNKKVRRAPLSEGPHSLGCYNPMMEDGISYTTLRFPEMNIPRTGDAESSEMQRPPPDCDDTVTYSALHKRQVGDYENVIPDFPEDEGIHYSELIQFGVGERPQAQENVDYVILKH
Mol* PDB structure viewerUniLectin3D
Ligand
Glycan ligands from structural data
![](../templates/png/NeuAc(a2-6)Gal(b1-4)Glc.png)
References
NCBI References (10 PubMed Identifiers)
- CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. [34642489]
- Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments. [34638774]
- The Protein Tyrosine Phosphatase SHP-1 (PTPN6) but Not CD45 (PTPRC) Is Essential for the Ligand-Mediated Regulation of CD22 in BCR-Ligated B Cells. [33990399]
- Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B-Cell Lymphoma Therapy. [33314603]
- Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia. [32648276]
- A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. [7618087]
- Regulation of CD45 engagement by the B-cell receptor CD22. [7537381]
- Identification and characterization of the murine homologue of CD22, a B lymphocyte-restricted adhesion molecule. [1401903]
- cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions. [1985119]
- The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion. [1691828]
UniProt Main References (8 PubMed Identifiers)
- Genomic structure and chromosomal mapping of the human CD22 gene. [8496602]
- The DNA sequence and biology of human chromosome 19. [15057824]
- The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). [15489334]
- Identification of the gene variations in human CD22. [10079291]
- Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition. [8463235]
- Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22. [8647200]
- CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation. [8627166]
- CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. [9143697]
All isoforms of this gene containing a lectin domain
RNA
RNA (Transcript ID: NM_001771.4)
m7G-5')ppp(5'-AGAUGCUGCCAGGGUCCCUGAAGAGGGAAGACACGCGGAAACAGGCUUGCACCCAGACACGACACCAUGCAUCUCCUCGGCCCCUGGCUCCUGCUCCUGGUUCUAGAAUACUUGGCUUUCUCUGACUCAAGUAAAUGGGUUUUUGAGCACCCUGAAACCCUCUACGCCUGGGAGGGGGCCUGCGUCUGGAUCCCCUGCACCUACAGAGCCCUAGAUGGUGACCUGGAAAGCUUCAUCCUGUUCCACAAUCCUGAGUAUAACAAGAACACCUCGAAGUUUGAUGGGACAAGACUCUAUGAAAGCACAAAGGAUGGGAAGGUUCCUUCUGAGCAGAAAAGGGUGCAAUUCCUGGGAGACAAGAAUAAGAACUGCACACUGAGUAUCCACCCGGUGCACCUCAAUGACAGUGGUCAGCUGGGGCUGAGGAUGGAGUCCAAGACUGAGAAAUGGAUGGAACGAAUACACCUCAAUGUCUCUGAAAGGCCUUUUCCACCUCAUAUCCAGCUCCCUCCAGAAAUUCAAGAGUCCCAGGAAGUCACUCUGACCUGCUUGCUGAAUUUCUCCUGCUAUGGGUAUCCGAUCCAAUUGCAGUGGCUCCUAGAGGGGGUUCCAAUGAGGCAGGCUGCUGUCACCUCGACCUCCUUGACCAUCAAGUCUGUCUUCACCCGGAGCGAGCUCAAGUUCUCCCCACAGUGGAGUCACCAUGGGAAGAUUGUGACCUGCCAGCUUCAGGAUGCAGAUGGGAAGUUCCUCUCCAAUGACACGGUGCAGCUGAACGUGAAGCACACCCCGAAGUUGGAGAUCAAGGUCACUCCCAGUGAUGCCAUAGUGAGGGAGGGGGACUCUGUGACCAUGACCUGCGAGGUCAGCAGCAGCAACCCGGAGUACACGACGGUAUCCUGGCUCAAGGAUGGGACCUCGCUGAAGAAGCAGAAUACAUUCACGCUAAACCUGCGCGAAGUGACCAAGGACCAGAGUGGGAAGUACUGCUGUCAGGUCUCCAAUGACGUGGGCCCGGGAAGGUCGGAAGAAGUGUUCCUGCAAGUGCAGUAUGCCCCGGAACCUUCCACGGUUCAGAUCCUCCACUCACCGGCUGUGGAGGGAAGUCAAGUCGAGUUUCUUUGCAUGUCACUGGCCAAUCCUCUUCCAACAAAUUACACGUGGUACCACAAUGGGAAAGAAAUGCAGGGAAGGACAGAGGAGAAAGUCCACAUCCCAAAGAUCCUCCCCUGGCACGCUGGGACUUAUUCCUGUGUGGCAGAAAACAUUCUUGGUACUGGACAGAGGGGCCCGGGAGCUGAGCUGGAUGUCCAGUAUCCUCCCAAGAAGGUGACCACAGUGAUUCAAAACCCCAUGCCGAUUCGAGAAGGAGACACAGUGACCCUUUCCUGUAACUACAAUUCCAGUAACCCCAGUGUUACCCGGUAUGAAUGGAAACCCCAUGGCGCCUGGGAGGAGCCAUCGCUUGGGGUGCUGAAGAUCCAAAACGUUGGCUGGGACAACACAACCAUCGCCUGCGCAGCUUGUAAUAGUUGGUGCUCGUGGGCCUCCCCUGUCGCCCUGAAUGUCCAGUAUGCCCCCCGAGACGUGAGGGUCCGGAAAAUCAAGCCCCUUUCCGAGAUUCACUCUGGAAACUCGGUCAGCCUCCAAUGUGACUUCUCAAGCAGCCACCCCAAAGAAGUCCAGUUCUUCUGGGAGAAAAAUGGCAGGCUUCUGGGGAAAGAAAGCCAGCUGAAUUUUGACUCCAUCUCCCCAGAAGAUGCUGGGAGUUACAGCUGCUGGGUGAACAACUCCAUAGGACAGACAGCGUCCAAGGCCUGGACACUUGAAGUGCUGUAUGCACCCAGGAGGCUGCGUGUGUCCAUGAGCCCGGGGGACCAAGUGAUGGAGGGGAAGAGUGCAACCCUGACCUGUGAGAGCGACGCCAACCCUCCCGUCUCCCACUACACCUGGUUUGACUGGAAUAACCAAAGCCUCCCCUACCACAGCCAGAAGCUGAGAUUGGAGCCGGUGAAGGUCCAGCACUCGGGUGCCUACUGGUGCCAGGGGACCAACAGUGUGGGCAAGGGCCGUUCGCCUCUCAGCACCCUCACCGUCUACUAUAGCCCGGAGACCAUCGGCAGGCGAGUGGCUGUGGGACUCGGGUCCUGCCUCGCCAUCCUCAUCCUGGCAAUCUGUGGGCUCAAGCUCCAGCGACGUUGGAAGAGGACACAGAGCCAGCAGGGGCUUCAGGAGAAUUCCAGCGGCCAGAGCUUCUUUGUGAGGAAUAAAAAGGUUAGAAGGGCCCCCCUCUCUGAAGGCCCCCACUCCCUGGGAUGCUACAAUCCAAUGAUGGAAGAUGGCAUUAGCUACACCACCCUGCGCUUUCCCGAGAUGAACAUACCACGAACUGGAGAUGCAGAGUCCUCAGAGAUGCAGAGACCUCCCCCGGACUGCGAUGACACGGUCACUUAUUCAGCAUUGCACAAGCGCCAAGUGGGCGACUAUGAGAACGUCAUUCCAGAUUUUCCAGAAGAUGAGGGGAUUCAUUACUCAGAGCUGAUCCAGUUUGGGGUCGGGGAGCGGCCUCAGGCACAAGAAAAUGUGGACUAUGUGAUCCUCAAACAUUGACACUGGAUGGGCUGCAGCAGAGGCACUGGGGGCAGCGGGGGCCAGGGAAGUCCCCGAGUUUCCCCAGACACCGCCACAUGGCUUCCUCCUGCGCGCAUGUGCGCACACACACACACACACGCACACACACACACACACACUCACUGCGGAGAACCUUGUGCCUGGCUCAGAGCCAGUCUUUUUGGUGAGGGUAACCCCAAACCUCCAAAACUCCUGCCCCUGUUCUCUUCCACUCUCCUUGCUACCCAGAAAUCCAUCUAAAUACCUGCCCUGACAUGCACACCUCCCCCUGCCCCCACCACGGCCACUGGCCAUCUCCACCCCCAGCUGCUUGUGUCCCUCCUGGGAUCUGCUCGUCAUCAUUUUUCCUUCCCUUCUCCAUCUCUCUGGCCCUCUACCCCUGAUCUGACAUCCCCACUCACGAAUAUUAUGCCCAGUUUCUGCCUCUGAGGGAAAGCCCAGAAAAGGACAGAAACGAAGUAGAAAGGGGCCCAGUCCUGGCCUGGCUUCUCCUUUGGAAGUGAGGCAUUGCACGGGGAGACGUACGUAUCAGCGGCCCCUUGACUCUGGGGACUCCGGGUUUGAGAUGGACACACUGGUGUGGAUUAACCUGCCAGGGAGACAGAGCUCACAAUAAAAAUGGCUCAGAUGCCACUUCAAAGAA-3'- Poly-A tail
- Coding region
DNA
DNA (Gene ID: 933)
CD22 molecule
strand +
SIGLEC-2, SIGLEC2
NCBI CDS gene sequence (2544 bp)
5'-ATGCATCTCCTCGGCCCCTGGCTCCTGCTCCTGGTTCTAGAATACTTGGCTTTCTCTGACTCAAGTAAATGGGTTTTTGAGCACCCTGAAACCCTCTACGCCTGGGAGGGGGCCTGCGTCTGGATCCCCTGCACCTACAGAGCCCTAGATGGTGACCTGGAAAGCTTCATCCTGTTCCACAATCCTGAGTATAACAAGAACACCTCGAAGTTTGATGGGACAAGACTCTATGAAAGCACAAAGGATGGGAAGGTTCCTTCTGAGCAGAAAAGGGTGCAATTCCTGGGAGACAAGAATAAGAACTGCACACTGAGTATCCACCCGGTGCACCTCAATGACAGTGGTCAGCTGGGGCTGAGGATGGAGTCCAAGACTGAGAAATGGATGGAACGAATACACCTCAATGTCTCTGAAAGGCCTTTTCCACCTCATATCCAGCTCCCTCCAGAAATTCAAGAGTCCCAGGAAGTCACTCTGACCTGCTTGCTGAATTTCTCCTGCTATGGGTATCCGATCCAATTGCAGTGGCTCCTAGAGGGGGTTCCAATGAGGCAGGCTGCTGTCACCTCGACCTCCTTGACCATCAAGTCTGTCTTCACCCGGAGCGAGCTCAAGTTCTCCCCACAGTGGAGTCACCATGGGAAGATTGTGACCTGCCAGCTTCAGGATGCAGATGGGAAGTTCCTCTCCAATGACACGGTGCAGCTGAACGTGAAGCACACCCCGAAGTTGGAGATCAAGGTCACTCCCAGTGATGCCATAGTGAGGGAGGGGGACTCTGTGACCATGACCTGCGAGGTCAGCAGCAGCAACCCGGAGTACACGACGGTATCCTGGCTCAAGGATGGGACCTCGCTGAAGAAGCAGAATACATTCACGCTAAACCTGCGCGAAGTGACCAAGGACCAGAGTGGGAAGTACTGCTGTCAGGTCTCCAATGACGTGGGCCCGGGAAGGTCGGAAGAAGTGTTCCTGCAAGTGCAGTATGCCCCGGAACCTTCCACGGTTCAGATCCTCCACTCACCGGCTGTGGAGGGAAGTCAAGTCGAGTTTCTTTGCATGTCACTGGCCAATCCTCTTCCAACAAATTACACGTGGTACCACAATGGGAAAGAAATGCAGGGAAGGACAGAGGAGAAAGTCCACATCCCAAAGATCCTCCCCTGGCACGCTGGGACTTATTCCTGTGTGGCAGAAAACATTCTTGGTACTGGACAGAGGGGCCCGGGAGCTGAGCTGGATGTCCAGTATCCTCCCAAGAAGGTGACCACAGTGATTCAAAACCCCATGCCGATTCGAGAAGGAGACACAGTGACCCTTTCCTGTAACTACAATTCCAGTAACCCCAGTGTTACCCGGTATGAATGGAAACCCCATGGCGCCTGGGAGGAGCCATCGCTTGGGGTGCTGAAGATCCAAAACGTTGGCTGGGACAACACAACCATCGCCTGCGCAGCTTGTAATAGTTGGTGCTCGTGGGCCTCCCCTGTCGCCCTGAATGTCCAGTATGCCCCCCGAGACGTGAGGGTCCGGAAAATCAAGCCCCTTTCCGAGATTCACTCTGGAAACTCGGTCAGCCTCCAATGTGACTTCTCAAGCAGCCACCCCAAAGAAGTCCAGTTCTTCTGGGAGAAAAATGGCAGGCTTCTGGGGAAAGAAAGCCAGCTGAATTTTGACTCCATCTCCCCAGAAGATGCTGGGAGTTACAGCTGCTGGGTGAACAACTCCATAGGACAGACAGCGTCCAAGGCCTGGACACTTGAAGTGCTGTATGCACCCAGGAGGCTGCGTGTGTCCATGAGCCCGGGGGACCAAGTGATGGAGGGGAAGAGTGCAACCCTGACCTGTGAGAGCGACGCCAACCCTCCCGTCTCCCACTACACCTGGTTTGACTGGAATAACCAAAGCCTCCCCTACCACAGCCAGAAGCTGAGATTGGAGCCGGTGAAGGTCCAGCACTCGGGTGCCTACTGGTGCCAGGGGACCAACAGTGTGGGCAAGGGCCGTTCGCCTCTCAGCACCCTCACCGTCTACTATAGCCCGGAGACCATCGGCAGGCGAGTGGCTGTGGGACTCGGGTCCTGCCTCGCCATCCTCATCCTGGCAATCTGTGGGCTCAAGCTCCAGCGACGTTGGAAGAGGACACAGAGCCAGCAGGGGCTTCAGGAGAATTCCAGCGGCCAGAGCTTCTTTGTGAGGAATAAAAAGGTTAGAAGGGCCCCCCTCTCTGAAGGCCCCCACTCCCTGGGATGCTACAATCCAATGATGGAAGATGGCATTAGCTACACCACCCTGCGCTTTCCCGAGATGAACATACCACGAACTGGAGATGCAGAGTCCTCAGAGATGCAGAGACCTCCCCCGGACTGCGATGACACGGTCACTTATTCAGCATTGCACAAGCGCCAAGTGGGCGACTATGAGAACGTCATTCCAGATTTTCCAGAAGATGAGGGGATTCATTACTCAGAGCTGATCCAGTTTGGGGTCGGGGAGCGGCCTCAGGCACAAGAAAATGTGGACTATGTGATCCTCAAACATTGA-3'
By using this site you agree to our privacy policy.
Please confirm you agree with the privacy policy before using the site.